Pharmaceutical Executive June 2013

June 2013 | Volume 0, Issue 0
Country Report
By Pharmaceutical Executive Editors
Ireland has been a pharma industry darling since the 1960s, when a then-newly established IDA targeted the sector as a strategic area for development. Today, the numbers are eyecatching. As reported by the IDA, nine out of the top 10 pharma companies in the world have substantial manufacturing operations in Ireland.
From the Editor
Getting patients to take their medicine on spec and on time is the challenge that never goes away—it's the deadweight baggage accompanying every industry innovation since the arrival of aspirin a century ago.
By Pharmaceutical Executive Editors
What is really driving decision making by the new Brazilian HTA agency? A look at appraisals issued in the first year.
New stakeholders, innovative technologies, and emergent synergies in government are combining to build fresh momentum behind the old issue of medication adherence. The question is will Big Pharma be flexible enough to keep pace with the changes?
Led by two New Yorkers with a mindset that marries novel scientific insights to the processing power of novel technologies, Regeneron's success is a revolutionary challenge to the industry status quo.
By Pharmaceutical Executive Editors
Despite their high status, management gurus aren't always on point when it comes to pharma, writes John Ansell.
The backlash against high prices for new medicines will impact research, patent exclusivity, and drug benefits.
By Pharmaceutical Executive Editors
Customer-focused supply-chain capabilities are becoming a more important part of a company's competitive advantage.
By Pharmaceutical Executive Editors
Compounders are under increased scrutiny following last year's spinal meningitis outbreak.
Project Data Sphere aims to liberate clinical trial data sets from industry and academic vaults, in an attempt to catalyze cancer research and discovery.
lorem ipsum